Media Invitation - Montreal-based Esperas Pharma Inc. to announce an important investment in a new anti-cancer treatment entering clinical trials

In collaboration with Q-CROC, the trial will be held at several major Montreal hospitals

MONTREAL, April 7, 2016 /CNW Telbec/ - In presence of Mr. Denis Coderre, Mayor of Montreal, Caroline Fortier, CEO of Esperas Pharma, Gaétan Morin, President and CEO of the Fonds de solidarité FTQ, and Luc Marengere, Managing Partner, of TVM Capital invite members of the media to attend a press conference announcing the start of the first-in-man clinical trial of ESP-01, an oral anti-cancer agent. The trial for this promising new treatment option will be run by Esperas Pharma Inc. in partnership with the Quebec Clinical Research Organization in Cancer (Q-CROC).



April 11, 2016
9:00 a.m.: Beginning of news conference and speeches 
9:30 a.m.: Individual interviews and photo opportunities


The Honourable Denis Coderre, Mayor of Montreal
Gaétan Morin, President and CEO, Fonds de solidarité FTQ
Dr. Fabrice Brunet, President and Chief Executive Officer, CHUM and CHU Sainte-Justine
Luc Marengere, Managing Partner, TVM Capital
Dr. Gerald Batist, Scientific Director, Q-CROC, and Dr. Fred Saad, Director of clinical research in uro-oncology and Chair of the Board, Q-CROC
Caroline Fortier, CEO, Esperas Pharma Inc.


Centre de recherche du CHUM - Pavilion R (in the lobby)
900 St-Denis St.
Montreal, Québec
H2X 0A9



For further information: Media Contact: Marie-Christine Garon, Cabinet de relations publiques NATIONAL, 514-409-0031,; Alex-Sandra Thibault, Cabinet de relations publiques NATIONAL, 514-843-2375,

Organization Profile

TVM Capital

More on this organization

Esperas Pharma inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890